Histone deacetylases 3 (HDAC3) is highly expressed in cervical cancer and inhibited by siRNA

Objective: To detect the expression of histone deacetylase 3 (HDAC3) in cervical cancer tissue and investigate the inhibition of HDAC3 by Small Interference RNA (siRNA) on the effect of HDAC3 in Hela cell line of cervical cancer. Methods: The expression of HDAC3 in 12 specimens of normal cervical tissues, 21 specimens of moderate to severe cervical intraepithelial neoplasia and 64 specimens of cervical carcinoma were measured by reverse transcription-Polymerase Chain Reaction (RT-PCR) and immunohistochemistry (IHC). RT-PCR and Western blotting were used to detect the expression of HDAC3 in Hela after transfected with siRNA and control RNA. Results: The expression levels of HDAC3 mRNA in normal cervical epithelia, CIN II similar to III and cervical cancer were (0.110 +/- 0.020), (0.756 +/- 0.065) and (0.310 +/- 0.021) respectively. The rate of HDAC3 positive expression in normal cervical epithelia, CIN II similar to III and cervical cancer were 8% (1/12), 38% (8/21), 94% (60/64) respectively. Significant down-regulation of the expression of mRNA and protein levels of HDAC3 was found following transfection of the HDAC3 siRNA. The results of IHC revealed that there were relationship between the expression of HDAC3 protein and the degree of tumor differentiation, myometrial invasion and lymph node metastasis. Conclusions: HDAC3 may play an important role in the course of cervical cancer. The in vitro transient transfection of synthesized HDAC3-siRAN on the Hela cell line can down-regulate the expression of mRNA and protein levels in the cells. siRNA is likely to be a new way to treating the cervical cancer.